Observed adalimumab effectiveness at week 12
| Patient group | DAS28* | HAQ DI (0−3)* | TJC (0−28) | SJC (0−28) | CRP (mg/l) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Absolute change | Percentage change | Absolute change | Percentage change | Absolute change | Percentage change | Absolute change | Percentage change | Absolute change | Percentage change | |
| AM, antimalarials; AZA, azathioprine; CRP, C-reactive protein; CsA, ciclosporin; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; HAQ DI, Health Assessment Questionnaire Disability Index; LEF, leflunomide; MTX, methotrexate; SJC, swollen joint count; SSZ, sulfasalazine; TJC, tender joint count. | ||||||||||
| Absolute change is given as mean (SD) or median. | ||||||||||
| *All changes in DAS28 and HAQ DI scores were significantly improved compared with baseline values (p⩽0.001). | ||||||||||
| †Of these 84 patients, 51% were receiving AZA, 27% were receiving parenteral gold, 17% were receiving CsA, and 5% were receiving penicillamine. | ||||||||||
| All patients (n = 6610) | −2.1 (1.4) | −35.4 | −0.54 (0.61) | −34.0 | −8.0 | −73.3 | −6.0 | −72.7 | −5.5 | −44.4 |
| Number of concomitant DMARDs | ||||||||||
| No DMARDs (n = 1731) | −1.9 (1.4) | −29.7 | −0.47 (0.63) | −27.2 | −7.0 | −66.7 | −6.0 | −66.7 | −4.5 | −31.4 |
| ⩾1 DMARD (n = 4879) | −2.2 (1.3) | −37.3 | −0.56 (0.60) | −36.4 | −8.0 | −75.0 | −6.0 | −75.0 | −5.7 | −47.8 |
| 1 DMARD (n = 4004) | −2.2 (1.3) | −37.2 | −0.56 (0.6) | −36.3 | −8.0 | −75.0 | −6.0 | −75.0 | −5.5 | −47.3 |
| 2 DMARDs (n = 769) | −2.3 (1.3) | −38.0 | −0.56 (0.6) | −36.8 | −8.0 | −75.0 | −6.0 | −75.0 | −7.0 | −50.5 |
| ⩾3 DMARDs (n = 106) | −2.3 (1.3) | −39.6 | −0.56 (0.57) | −35.2 | −9.0 | −80.0 | −7.0 | −75.0 | −5.7 | −50.7 |
| 1 exclusive concomitant DMARD | ||||||||||
| MTX (n = 2794) | −2.3 (1.3) | −38.3 | −0.58 (0.6) | −38.4 | −8.0 | −75.0 | −6.0 | −75.0 | −5.4 | −47.5 |
| LEF (n = 842) | −2.0 (1.3) | −33.7 | −0.49 (0.59) | −29.5 | −8.0 | −75.0 | −6.0 | −69.2 | −5.4 | −44.6 |
| AM (n = 148) | −2.4 (1.4) | −37.9 | −0.72 (0.63) | −46.0 | −9.0 | −75.0 | −7.0 | −79.2 | −8.1 | −52.3 |
| SSZ (n = 133) | −2.1 (1.3) | −34.2 | −0.52 (0.62) | −29.6 | −7.0 | −66.7 | −6.0 | −66.7 | −8.9 | −54.2 |
| 1 other DMARD† (n = 84) | −2.2 (1.2) | −35.1 | −0.55 (0.55) | –27.1 | −8.0 | −72.1 | −7.0 | −68.4 | −9.7 | −49.2 |
| DMARD combinations | ||||||||||
| MTX+LEF (n = 180) | −2.2 (1.3) | −36.4 | −0.54 (0.58) | −36.3 | −9.0 | −76.9 | −7.0 | −78.9 | −6.0 | −46.2 |
| MTX+AM (n = 269) | −2.4 (1.3) | −39.2 | −0.63 (0.66) | −41.3 | −8.0 | −76.3 | −6.0 | −76.4 | −4.7 | −51.4 |
| MTX+SSZ (n = 182) | −2.4 (1.3) | −39.8 | −0.55 (0.52) | −38.8 | −8.0 | −76.4 | −6.0 | −75.0 | −10.1 | −56.7 |
| MTX+SSZ+AM (n = 76) | −2.4 (1.3) | −40.7 | −0.58 (0.59) | −37.6 | −7.0 | −80.0 | −7.0 | −75.8 | −7.8 | −55.2 |